The CNMSC Pediatric Working Group recently published a scoping review examining the availability and use of disease modifying therapies (DMTs) in pediatric-MS to better understand the potential barriers to use.
The researchers reviewed observational studies examining DMT use in pediatric-MS published between 1993 and 2024. Eighty-eight studies that describe real-world, regionally specific DMT use for 21,591 children/youth with MS were reviewed. All 88 studies had at least 10 participants 18-years of age or younger that had ever used a DMT. This is one of the largest reviews to date of real-world DMT use in pediatric-MS.
Overall use of DMTs in pediatric-MS is low with distinct differences in different countries and regions. In addition to the barriers to access all people with MS face, pediatric-specific barriers exist stemming from the rarity of pediatric-onset MS and the lack of DMT trials needed for regulatory approval and coverage. While few DMT trials in pediatric-MS have been done, many observational studies provide real-world evidence of safety and effectiveness of most approved MS therapies. Given the potential for devastating outcomes in pediatric-MS if left untreated, providing access to treatment is critical. Further research is needed to understand regional barriers to treatment and enable appropriate, timely and equitable care for all children and youth with MS.